Heterotropic allosteric modulation of CYP3A4 in vitro by progesterone: Evidence for improvement in prediction of time-dependent inhibition for macrolides
Drug Metabolism and Disposition · 2025
DOI: 10.1124/dmd.124.001820 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Luc R A Rougée und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. Electronic address: lrougee@lilly.com. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Erythromycin, Progesterone, Cytochrome P-450 CYP3A Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. Electronic address: lrougee@lilly.com.
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Zitieren
APA
Rougée, L. R. A., Hegde, P. V., Shin, K., Abraham, T. L., Bell, A., & Hall, S. D. (2025). Heterotropic allosteric modulation of CYP3A4 in vitro by progesterone: Evidence for improvement in prediction of time-dependent inhibition for macrolides. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.124.001820
Vancouver
Rougée LRA, Hegde PV, Shin K, Abraham TL, Bell A, Hall SD. Heterotropic allosteric modulation of CYP3A4 in vitro by progesterone: Evidence for improvement in prediction of time-dependent inhibition for macrolides. Drug Metabolism and Disposition. 2025. doi:10.1124/dmd.124.001820
BibTeX
@article{Rouge2025,
author = {Rougée, Luc R A and Hegde, Pooja V and Shin, Kaitlin and Abraham, Trent L and Bell, Alec and Hall, Stephen D},
title = {Heterotropic allosteric modulation of CYP3A4 in vitro by progesterone: Evidence for improvement in prediction of time-dependent inhibition for macrolides},
journal = {Drug Metabolism and Disposition},
year = {2025},
doi = {10.1124/dmd.124.001820}
}
EUVIMED